Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.50 |
| ▸ | MAOA | P21397 | 5/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | CALML3 | P27482 | 1/20 | 0.49 |
| ▸ | SDHA | P31040 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5378911 | 0.93 | F10 (0.51) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL14370655 | 0.93 | F10 (0.51) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL4883522 | 0.92 | MAOA (0.51) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL4879564 | 0.90 | MAOA (0.62) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL5382914 | 0.89 | MAOA (0.47) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL14370653 | 0.89 | MAOB (0.55) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL5380355 | 0.89 | MAOB (0.55) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL5378887 | 0.88 | MAOB (0.63) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL5380337 | 0.86 | MAOA (0.49) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL5370538 | 0.86 | MAOB (0.59) | F10MAOAMAOBLMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279494-B2 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | PFIZER INC. (US) | 2007-10-09 | — | — | US | claimed |
| US-20050192325-A1 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | RENSLO ADAM (US) | 2005-09-01 | — | — | US | claimed |
| US-7279494-B2 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | PFIZER INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-20050192325-A1 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | RENSLO ADAM (US) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192325-A1 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | OXA1L, CYP51A1, CYP2C19 | F10 3090/4885MAOA 1957/4885MAOB 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.